Dupixent/Dubrantis 200 mg / 300 mg Solution for injection.
PDF Leaflet Revision Date: 15 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and prurigo nodularis.
Dosage (summary)
Adults: Initial 600 mg, then 300 mg every 2 weeks for atopic dermatitis; 400 mg initial, then 200 mg every 2 weeks for asthma.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Live vaccines
- CYP450 substrates
Contraindications
- Hypersensitivity to dupilumab or excipients
Common side effects
- Conjunctivitis
- Injection site reactions
- Eosinophilia
Counselling Points
- Administer subcutaneously
- Rotate injection sites
- Report eye symptoms
Serious warnings
- Hypersensitivity reactions
- Conjunctivitis and keratitis
- Eosinophilic conditions
Important Disclaimer
The Dupixent/Dubrantis 200 mg / 300 mg Solution for injection. professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
